SEARCH

SEARCH BY CITATION

References

  • 1
    Nordin J, Parker E, Vazquez-Benitez G, et al. Safety of the yellow fever vaccine: a retrospective study. J Travel Med 2013; 20:368373.
  • 2
    Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine 2011; 29:45444555.
  • 3
    Thomas RE, Lorenzetti DL, Spragins W, et al. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf 2011; 6:145154.
  • 4
    Gershman MD, Staples JE, Bentsi-Enchill AD, et al. Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2012; 30:50385058.
  • 5
    Sejvar JJ, Kohl KS, Bilynsky R, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:57715792.
  • 6
    Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599612.
  • 7
    Rűggeberg JU, Gold MS, Bayas J-M, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007; 25:56755684.
  • 8
    Gold MS, Gidudu J, Erlewyn-Lajeunesse M, Law B; Brighton Collaboration Working Group on Anaphylaxis. Can the Brighton Collaboration case definitions be used to improve the quality of Adverse Event Following Immunization (AEFI) reporting? Anaphylaxis as a case study. Vaccine 2010; 28:44874498.
  • 9
    Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26:60776082.
  • 10
    Lawrence G, Menzies R, Burgess M, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003; 27:307323.
  • 11
    Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004; 28:244248.
  • 12
    de Menezes Martins R, de Lourdes S Maia M, dos Santos EM, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Proc Vaccinol 2010; 2:178183.
  • 13
    Monath TP, Cetron MS, McCarthy K, et al. Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 2005; 1:207214.
  • 14
    Schumachera Z, Bourquin C, Heininger U. Surveillance for adverse events following immunization (AEFI) in Switzerland—1991-2001. Vaccine 2010; 28:40594064.
  • 15
    Thomas RE, Lorenzetti DL, Spragins W, et al. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 2012; 86:359372.